Abbott Will Outlicense Ketolide Antibiotic, Focus On Quinolone And D2E7
Executive Summary
Abbott is seeking to outlicense its ketolide antibiotic ABT-773 in lieu of expanding Phase III development to address class issues
You may also be interested in...
Abbott Abbokinase Relaunches With Limited Indication, Without Bold Warning
Abbott Abbokinase labeling carries the more limited indication of pulmonary embolism following re-approval of the thrombolytic Oct. 10
Pediatric Studies for PPIs: Are Placebo-Controlled Trials In Infants Unethical?
FDA is asking its pediatric advisory subcommittee to consider whether the agency's requirements for pediatric studies of proton pump inhibitors in infants under one year of age raise ethical concerns
TAP Prevacid Consumer Campaign Will Include Nexium Comparison
TAP's Prevacid consumer promotions will include study data comparing the product to AstraZeneca's Nexium (esomeprazole) that will be published by the end of March